Form 4: Adaptive Biotechnologies Officer Sells Shares

Adaptive Biotechnologies' Chief Commercial Officer, Sharon Benzeno, executed a pre-planned sale of 12,604 common shares following option exercises.

Summary

• Sharon Benzeno, Chief Commercial Officer of Adaptive Biotechnologies Corp (ADPT), engaged in transactions on December 4, 2025.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on August 18, 2025.
• Benzeno exercised stock options to acquire a total of 12,604 common shares.
• The options were exercised at prices of $12.14 (4,290 shares), $8.46 (4,157 shares), and $3.99 (4,157 shares).
• Concurrently, 12,604 common shares were sold at a weighted average price of $16.85 per share, with prices ranging from $16.66 to $16.93.
• Following these transactions, Benzeno's direct beneficial ownership of common stock is 296,791 shares.
• Remaining unexercised stock options include 12,871 at an exercise price of $12.14, 62,360 at $8.46, and 112,247 at $3.99.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction (exercise and sell) executed under a 10b5-1 plan, which typically does not carry strong positive or negative sentiment regarding the company's prospects.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, non-public information.
• The sale price of $16.85 is higher than the exercise prices of $12.14, $8.46, and $3.99, indicating a profitable exercise and sale for the officer.

Negatives

• The Chief Commercial Officer sold 12,604 shares, reducing their direct beneficial ownership of common stock.

Industry Context

This filing represents a routine insider transaction, common for executives managing their equity compensation. It does not provide specific insights into broader industry trends or competitive positioning for Adaptive Biotechnologies.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be perceived as a slight negative, though mitigated by the 10b5-1 plan. The overall impact on the company's stock price is likely minimal given the routine nature and relatively small volume compared to total outstanding shares.

Key Dates

Recommendation

This Form 4 details a routine, pre-planned insider transaction (exercise of options and subsequent sale of shares) by a Chief Commercial Officer. Such transactions, especially when conducted under a Rule 10b5-1 plan, are generally for personal financial planning and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. The volume of shares sold is not significant enough to suggest a strong bearish signal, nor does the exercise of options at lower prices provide a strong bullish signal beyond the executive realizing compensation. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information to alter an existing investment thesis.

Keywords

Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Stock Options, Share Sale, Rule 10b5-1, Sharon Benzeno, Chief Commercial Officer